Discover
llllllllll ontamalimab (SHP647) / TakedaEfficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) (clinicaltrials.gov) - Aug 19, 2020 - P3; N=1032; Active, not recruiting; Sponsor: Shire; Trial completion date: Aug 2021 --> Aug 2020; Trial primary completion date: Aug 2021 --> Aug 2020llllllllll Cimzia (certolizumab pegol) / Astellas, UCB, Eli LillyHighmark Forges Outcomes-Based Contract with UCB for Anti-Inflammatory Drug CIMZIA (certolizumab pegol) (PRWeb) - Aug 18, 2020 - "Highmark announced that it has entered an outcomes-based agreement with UCB, Inc. ('UCB') for UCB’s medication CIMZIA® (certolizumab pegol)...for adult patients with chronic inflammatory conditions that include Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis....With outcomes-based agreements between a pharmaceutical drug manufacturer and payer, reimbursement for a drug is based in part on its clinical effectiveness for those patients using the drug. If clinical outcomes are not met, the pharmaceutical drug manufacturer typically refunds part of the original purchase to the payer."llllllllll ontamalimab (SHP647) / TakedaFIGARO UC 302: Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Aug 19, 2020 - P3; N=740; Active, not recruiting; Sponsor: Shire; Trial completion date: Jul 2024 --> Oct 2020; Trial primary completion date: Jul 2024 --> Oct 2020llllllllll ontamalimab (SHP647) / TakedaFIGARO UC 301: Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov) - Aug 19, 2020 - P3; N=740; Active, not recruiting; Sponsor: Shire; Trial completion date: Jul 2024 --> Oct 2020; Trial primary completion date: Jul 2024 --> Oct 2020llllllllll ontamalimab (SHP647) / TakedaEfficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) (clinicaltrials.gov) - Aug 19, 2020 - P3; N=1032; Active, not recruiting; Sponsor: Shire; Trial completion date: Aug 2021 --> Oct 2020; Trial primary completion date: Aug 2021 --> Oct 2020llllllllll Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimA Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (clinicaltrials.gov) - Aug 19, 2020 - P3; N=1250; Recruiting; Sponsor: AbbVie; Trial primary completion date: Oct 2025 --> May 2026
